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Both pharmacologic and mechanical approaches designed to limit infarct size by recanaliza-
tion of infarct-related arteries have reduced mortality associated with ST-segment elevation
myocardial infarction (STEMI). Early efforts to combine the two were attenuated because of
complications encountered. Primary percutaneous coronary intervention (PCI) and throm-
bolysis became viewed as alternative rather than complementary modalities. Time to
recanalization and adequacy of restoration of perfusion were found to be pivotal determinants
of a favorable outcome with either approach. Because pharmacologic intervention can be
initiated immediately in virtually any hospital, it is a promising initial step. Because PCI
proffers more complete recanalization, it may be a particularly salutary initial or subsequent
step. Because of unavoidable delay often confronting implementation of PCI, optimal
advantage may accrue from the use of both approaches in combination. We seek to emphasize
the potential synergy by referring to the combined approach as “pharmacoinvasive recanali-
zation” rather than by the conventional term “facilitated PCI.” Virtually all patients with
STEMI can benefit from prompt, sustained, and complete coronary recanalization. Thus,
investigations focusing on identification of pharmacologic regimens that can safely initiate
recanalization as early as possible, minimize bleeding, and broaden the temporal window
available for efficacy of subsequent, optimally timed PCI should provide particularly valuable
information. (J Am Coll Cardiol 2003;42:646–51) © 2003 by the American College of
Cardiology Foundation
Coronary thrombolysis and primary-infarct percutaneous
coronary intervention (PCI) for treatment of ST-segment
elevation myocardial infarction (STEMI) are generally
viewed as alternatives. However, consideration of estab-
lished principles and much recent information support the
view that the two in combination offer potential synergies.
We shall refer to the combination, frequently called “facil-
itated PCI,” as “pharmacoinvasive recanalization” to em-
phasize the potential synergy and because it is not literally
the case that initial thrombolysis actually facilitates PCI.
Elucidation of the importance of time to recanalization
in early studies of coronary thrombolysis. Dr. Eugene
Braunwald formulated a then-revolutionary hypothesis. He
postulated that acute myocardial infarction (AMI) is a
dynamic process and that its clinical outcome is determined
largely by infarct size. The first laboratory study testing this
hypothesis concluded: “Of greatest interest, from the clini-
cal point of view, is the finding that the severity and extent
of myocardial ischemic injury resulting from coronary oc-
clusion could be radically altered not only by pretreatment
but also by an appropriate intervention as late as 3 h after
the coronary occlusion” (1). Two concepts emerged from
subsequent clinical studies and trials: 1) restoration of
coronary patency improves survival; and 2) recanalization
must be induced within a narrow temporal window to be
maximally beneficial (2–7).
The Fibrinolytic Therapy Trialists’ Collaborative Group
articulated results from clinical trials as follows: 35 lives
could be saved per thousand patients with STEMI when
treatment was initiated within the first hour after onset of
symptoms. By contrast, fewer, 16 per thousand, lives could
be saved when treatment had to be delayed for as long as 7
to 12 h (8). American College of Cardiology/American
Heart Association (ACC/AHA) AMI guidelines state that
“The earlier therapy begins, the better the outcome, with
the greatest benefit. . .when (thrombolytic) therapy is given
in the first 3 hours” (9).
Thrombolysis has reduced mortality associated with
STEMI. Adjusted hospital mortality decreased by nearly
50% between 1986 and 1997 as shown in the longitudinal
Worcester Heart Attack study. During this period the use of
thrombolytic agents doubled, even though primary angio-
plasty was used only minimally in most communities.
Although improvement was seen for both young and older
patients in the registry study (10), the use of thrombolysis
for treatment of elderly patients remained controversial
(11–14). A population-based cohort study of Medicare
beneficiaries presenting with STEMI during the 1990s
indicated that both thrombolysis and primary angioplasty
were associated with one-year survival benefits. However,
thrombolysis did not confer a clear survival benefit at 30
days (odds ratio, 1.01; 95% confidence interval, 0.94 to
1.09) (13). Ten lives were saved per thousand elderly
patients with STEMI according to the Fibrinolytic Therapy
Trialists Collaborative Group (8). However, the interpreta-
tion remains controversial given the insignificant p value
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and wide confidence intervals (95% confidence interval,
16 to 36.0) in the analysis.
The importance of complete restoration of myocardial
perfusion in studies of coronary thrombolysis and pri-
mary PCI. Despite its value, thrombolysis is clearly imper-
fect. Certain subsets of patients with STEMI (e.g., those
with cardiogenic shock) benefit unequivocally only from
acute infarct PCI with stenting (15). Thrombolysis fails to
induce complete recanalization and reperfusion (Thrombol-
ysis in Myocardial Infarction [TIMI] grade 3 flow) in 30%
to 40% of patients even with conjunctive antithrombotic
and antiplatelet regimens (16,17). In both the Thrombolytic
Trial of Eminase in Acute Myocardial Infarction
(TEAM)-3 and the European Cooperative Study Group
trials, outcome in patients with TIMI 2 flow after throm-
bolysis was suboptimal and more similar to outcome in
patients with persistently occluded culprit arteries than
outcome in those with completely recanalized vessels
(18,19).
Because of concerns regarding the safety and efficacy of
thrombolysis, PCI evolved as an attractive alternative. Its
value was supported by results in a small but highly
influential 56-patient randomized trial comparing primary
angioplasty with intracoronary administration of streptoki-
nase in 1986 (20). Primary angioplasty was superior with
respect to recovery of left ventricular function. The Primary
Angioplasty in Myocardial Infarction (PAMI) trial, a 395
patient randomized trial, compared primary angioplasty
with tissue-type plasminogen activator (t-PA). Early mor-
tality was more favorable with primary angioplasty (2.6%
compared with 6.5%, p  0.06). In 90% of patients
undergoing PCI, TIMI grade 3 flow was demonstrable (21).
Unfortunately, however, 25% of hospitals in the U.S.
and 10% in Europe have facilities for PCI. This has
limited widespread adoption of primary angioplasty (9,22).
The community-based Global Use of Strategies to Open
Occluded Arteries in Acute Coronary Syndromes (GUS-
TO) IIb substudy randomized 1,138 patients with STEMI
to t-PA or primary angioplasty. The incidence of the
primary end point (death, nonfatal reinfarction, or stroke at
30 days) was significantly lower with primary angioplasty
(9.6% compared with 13.7%, p  0.03) (23). Somewhat
surprisingly, however, the reduction in mortality was mod-
est (5.7% compared with 7.0%, p  0.37) compared with
the apparently striking reduction seen in the PAMI trial.
Neither the GUSTO IIb trial nor the National Registry of
Myocardial Infarction-2 data demonstrated statistically im-
proved survival in patients with STEMI treated with
primary angioplasty compared with fibrinolytic agents. This
observation discouraged widespread adoption of primary
angioplasty (24). The apparently greater mortality benefit in
PAMI may reflect, in part, inclusion of lower risk patients
(25) and the impact of the skill of operators performing a
high volume of procedures in the PAMI trial (26).
Longer times to treatment increase mortality after
STEMI. In GUSTO IIb, patients with arteries that were
opened 60 min after randomization had a 30-day mortal-
ity of only 1%. By contrast, mortality was 6.4% when the
delay was 90 min (27). Similarly, in National Registry of
Myocardial Infarction (NRMI)-2 mortality was 1.6 times
higher with primary angioplasty accomplished within 151 to
180 min after admission than that accomplished within
60 min (28). The 1999 update to the ACC/AHA
guidelines states: “Interventional cardiologists and centers
must operate within a specified corridor of outcomes to
include balloon dilation within 90 min (30) of admission
and diagnosis of AMI” (9).
It is instructive to consider the results in two trials
comparing primary angioplasty with thrombolysis in the
context of time to open artery—Danish Multicenter
Randomized Study of Acute Myocardial Infarction
(DANAMI)-2 and the Zwolle trial in the elderly (14,29).
Both sought to resolve the vexing issues of the frequent
delay inherent in the need for transfer of patients to centers
that can perform PCI and the relatively reduced benefit of
thrombolysis in elderly patients. The DANAMI-2 trial
showed a reduction in reinfarction even in patients requiring
transfer for primary angioplasty. The Zwolle trial demon-
strated reduced one-year mortality in very high risk, elderly
patients undergoing primary angioplasty compared with
thrombolysis. Should we, therefore, conclude that a “trans-
fer to a trauma center” strategy for PCI is needed, such that
all patients with STEMI undergo initial treatment in
centers performing PCI (12)? Not necessarily.
Rapidity of time to opening, completeness of restoration
of flow, and the promise of pharmacoinvasive recanali-
zation. A combined pharmacoinvasive approach capitaliz-
ing on the rapidity of initiation and widespread feasibility of
pharmacologic thrombolysis to promptly restore at least
some myocardial blood flow, coupled with the more com-
plete restoration achievable with subsequent PCI, merits
consideration as an optimal approach. Though this ap-
proach is frequently called “facilitated PCI,” we refer to it
here as “pharmacoinvasive recanalization” (Fig. 1).
Unfortunately, the benefit of primary PCI is limited—
frequently by unavoidable delay. The median door-to-
Abbreviations and Acronyms
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Cardiology/American Heart Association
AMI  acute myocardial infarction
GUSTO  Global Use of Strategies to Open
Occluded Arteries in Acute Coronary
Syndromes
PACT  Plasminogen-Activator Angioplasty
Compatibility Trial
PAMI  Primary Angioplasty in Myocardial
Infarction
PCI  percutaneous coronary intervention
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balloon times in DANAMI-2 for both on-site (90 min) and
transported patients (110 min) (29–31) do not mesh
closely with overall clinical experience in the U.S. The
NRMI data show a mean time of 111 min for the entire
patient group and 198 min for those requiring transfer
(30,32). In the Zwolle trial, the mean time was remarkably
low, 59  19 min (14). By contrast, the U.S. Medicare
experience shows an interval more than twice as long (143
min) (13). Primary PCI can restore flow virtually completely
in 90% of patients. Thus, it is clearly superior to coronary
thrombolysis with respect to this pivotal variable when it can
be performed in a 90  30 min time window (31,32).
However, in general, this constraint cannot be met in
community practice settings. Single centers have reduced
door-to-balloon times for primary PCI (33). System-wide
approaches (requiring major efforts on the part of personnel
in communities, emergency rooms, transport systems, and
primary angioplasty centers) might make timely primary
angioplasty more universally available (12). Yet, nationally,
it has been possible to reduce door-to-balloon times by only
8 min during the past decade (30,34).
In part because of recognized though different limitations
of each approach, many trials have compared PCI with
thrombolysis (32). They were designed to settle the debate
of “either-or” that had been forged by the historically based
presumption that “routine, immediate angioplasty does not
provide an improved outcome after thrombolytic adminis-
tration . . .” (31). This antipodal view of early PCI and
thrombolysis evolved because of a historical lack of clear-cut
superiority of either and a high incidence of adverse events
encountered with the two combined in early trials (35–38).
Recent results require reconsideration of the historically
based assumptions (39–42). They indicate that adverse
event rates can be diminished with the use of clot-selective
fibrinolytic agents, improved antiplatelet agents, and ad-
vances in PCI, including the use of stents (Table 1).
Recognition of potential synergies. The Plasminogen-
Activator Angioplasty Compatibility (PACT) trial random-
ized patients with STEMI to initial treatment with “half
dose” t-PA (50 mg) compared with placebo. All were
transferred to the catheterization laboratory for assessment
for immediate PCI as well. The initial thrombolysis doubled
the incidence of the presence of TIMI grade 3 flow at the
time of initial angiographic assessment (from 15% to 33%).
The combined recanalization strategy was not compromised
by early reocclusion or bleeding (40). Induction of a higher
incidence of TIMI grade 3 flow before PCI is relevant to
clinical outcome. Thus, mortality was fivefold greater with
primary angioplasty when therapy before PCI had not
induced TIMI grade 3 flow at the time of initial angiogra-
phy in the PAMI trials (43). Favorable findings regarding
regular use of PCI after thrombolysis in PACT and,
subsequently, in the Strategies for Patency Enhancement in
the Emergency Department (SPEED) and TIMI 10B/14B
substudies (39–42) (Table 1) are not reflected in current
ACC/AHA guidelines for management of STEMI. It is
unfortunate, in our view, that the guidelines presently
classify routine use of angiography and PCI within 24 h of
thrombolysis for treatment of STEMI as a class III contra-
indication (9). We believe that results in future trials,
coupled with information already available, are likely to
require modification of this guidance.
Elucidation of the efficacy of pharmacoinvasive recanal-
ization. Future trials of treatment of STEMI may be of
particular value if they focus on both the crucial importance
of combined rapidity of recanalization and the completeness
of restoration of myocardial blood flow. When PCI is
performed early after administration of thrombolytic drugs,
it is generally called “facilitated PCI.” Yet, PCI is not
simplified by antecedent therapy with thrombolytic agents.
It may be rendered more difficult. We believe that the focus
of research should deviate from the decade-long “either-or”
debate to elucidation of the best strategy of pharmacoinva-
sive recanalization by addressing the following five ques-
tions:
Table 1. Selected Studies Supporting the Concept of PharmacoInvasive Recanalization
Study Characteristics PACT SPEED TIMI 10B/14B
Publication date 1999 2000 2001
Total trial (n) 606 528 1,938
Early PCI after lytic (n) 302 323 719
Type of early PCI
Rescue PCI 39% 34% 41%
Facilitated PCI 61% 64% 59%
Study design* Randomized trial Substudy Substudy
Pre-PCI lytic 50 mg t-PA Combo Rx Combo Rx
Time to PCI 120 from presentation at 60–90 angio at 60–90 angio
Advantage of early PCI Doubled rate of TIMI 3 flow
at initial angiogram
Decrease in reinfarction and urgent
revascularization
54% reduction in death 
recurrent AMI
Increase in major bleeding due
to early PCI
No No No
Angio is protocol driven 60–90 min angiogram after drug dosing. *The PACT trial is a randomized comparison of the two strategies; the SPEED and TIMI 10B/14B
comparisons are retrospective analyses from subsets of patients undergoing early PCI in the dose-finding randomized trials.
AMI  acute myocardial infarction; Combo Rx  combination therapy and dose finding with thrombolytic agents and/or glycoprotein IIB/IIIA inhibitors; PACT 
Plasminogen-Activator Angioplasty Compatibility trial; PCI  percutaneous coronary intervention; SPEED  Strategies for Patency Enhancement in the Emergency
Department.
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1) What initial pharmacologic strategy for recanalization
can most safely maximize the achievement of TIMI
grade 3 flow by the time that initial angiography,
undertaken as early as possible, is performed? Candidates
include fibrinolysis with clot-selective drugs and the use
of conjunctive agents (17), including glycoprotein IIb/
IIIa inhibitors, platelet adenosine diphosphate antago-
nists, low-molecular-weight heparin, direct thrombin
inhibitors, and novel anticoagulants such as antagonists
of coagulation factors Xa and VIIa. Outcomes were
improved with the use of glycoprotein IIb/IIIa inhibitors
before primary PCI in the Abciximab Before Direct
Angioplasty and Stenting in MI Regarding Acute and
Long-Term Follow-Up (ADMIRAL) trial (although
not when they were used at the time of primary PCI in
the Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications [CADILLAC]
trial) (44,45). Because induction of early TIMI 3 flow is
more readily achieved with full-dose than with half-dose
fibrinolytic agents or glycoprotein IIb/IIIa inhibition
alone (16), such regimens may ultimately prove to be
superior with respect to mortality as well.
2) What initial pharmacologic regimen is optimally safe
when PCI is initiated very early afterward? The combi-
nation of half-dose fibrinolytic agents plus glycoprotein
IIb/IIIa inhibitors is an attractive option as judged from
results in pilot studies such as TIMI 14 (16). Unfortu-
nately, however, neither Assessment of the Safety and
Efficacy of a New Thrombolytic (ASSENT)-III nor
GUSTO V demonstrated greater efficacy than that seen
with full-dose thrombolytic agents plus low-molecular-
weight heparin. In fact, the incidence of bleeding was
greater, especially in elderly patients (46,47).
3) Can the temporal window for efficacy of PCI be broad-
ened by employing pharmacologic components as part of
the pharmacoinvasive recanalization strategy? Current
median times to open artery for non-transferred patients
(111 min) and transferred patients (198 min) imply that
community practice often cannot fulfill criteria recom-
mended for the timing of primary angioplasty
(9,30,31,34). Thus, studies are needed to define out-
comes in patients initially treated pharmacologically and
for whom mechanical intervention is not practically
possible for 3 h or more after onset of symptoms.
4) What is the best treatment strategy for elderly patients?
Only 10% of patients with STEMI in randomized trials
have been 75 years of age (8) because of several
considerations, including the limited benefits of throm-
bolysis in the elderly, the fact that only 40% of elderly
patients with STEMI present to hospitals with on-site
capability for PCI, and a natural inclination to seek to
enroll patients at low risk in randomized trials
(8,11,12,25,48). Optimal reduction of mortality after
STEMI requires that mortality be reduced in elderly
patients. Their mortality is as much as tenfold greater
than that of younger patients with STEMI (48). By
Figure 1. A hypothetical cumulative frequency distribution of time to Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow in patients treated for
ST-segment elevation myocardial infarction (STEMI) at a minority of hospitals with invasive capabilities and a majority of community hospitals that would
require transfer of patients with STEMI for primary angioplasty. Although 50% of patients could be expected to exhibit TIMI 3 flow with thrombolysis
in the first 60 min after hospital presentation, achievement of TIMI grade 3 flow in 90% of patients with STEMI requires a pharmacoinvasive recanalization
strategy and broadening the window during which benefit can be conferred. PCI  percutaneous coronary intervention.
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broadening the temporal window available for effective
PCI and including in studies more hospitals that lack the
capacity to perform PCI on their own premises, multi-
center studies of pharmacoinvasive recanalization could
enroll the elderly in proportions closer to their 30% to
40% representation among all patients with STEMI
(10).
5) Can novel secondary end points be used to decrease sizes
of populations in trials yet provide sufficient power for
detection of improved therapeutic efficacy? Microvascu-
lar flow is a powerful indicator and perhaps determinant
of prognosis after STEMI. Thus, end points such as
TIMI frame count, perfusion grade, and ST-segment
resolution are strong descriptors of outcomes (49). Use
of such end points should facilitate and may be of
importance in evaluating the efficacy of novel approaches
such as distal, embolic protection (50), and novel con-
junctive and adjunctive pharmacologic regimens.
Conclusions. As judged from established principles re-
garding determinants of prognosis, the rapidity of recanali-
zation and the magnitude of sustained restoration of perfu-
sion will continue to be pivotal variables in improving
treatment of patients with STEMI. We believe that phar-
macoinvasive recanalization is a particularly promising ap-
proach. Optimizing this modality may render irrelevant the
“either-or” debate that has pitted the virtues of thrombolysis
against those of PCI.
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